These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 28728694)
1. Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Word of Endorsement. Liebregts M; Vriesendorp PA; Ten Berg JM J Am Coll Cardiol; 2017 Jul; 70(4):481-488. PubMed ID: 28728694 [TBL] [Abstract][Full Text] [Related]
2. Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis. Osman M; Kheiri B; Osman K; Barbarawi M; Alhamoud H; Alqahtani F; Alkhouli M Clin Cardiol; 2019 Jan; 42(1):190-197. PubMed ID: 30421437 [TBL] [Abstract][Full Text] [Related]
3. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Leonardi RA; Kransdorf EP; Simel DL; Wang A Circ Cardiovasc Interv; 2010 Apr; 3(2):97-104. PubMed ID: 20197511 [TBL] [Abstract][Full Text] [Related]
4. Surgical septal myectomy or alcohol septal ablation: which approach offers better outcomes for patients with hypertrophic obstructive cardiomyopathy? Poon SS; Field M; Gupta D; Cameron D Interact Cardiovasc Thorac Surg; 2017 Jun; 24(6):951-961. PubMed ID: 28329292 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. Vriesendorp PA; Liebregts M; Steggerda RC; Schinkel AF; Willems R; Ten Cate FJ; van Cleemput J; Ten Berg JM; Michels M JACC Heart Fail; 2014 Dec; 2(6):630-6. PubMed ID: 25447346 [TBL] [Abstract][Full Text] [Related]
6. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy. Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093 [TBL] [Abstract][Full Text] [Related]
7. Choice of Septal Reduction Therapies and Alcohol Septal Ablation. Fifer MA Cardiol Clin; 2019 Feb; 37(1):83-93. PubMed ID: 30447719 [TBL] [Abstract][Full Text] [Related]
8. Alcohol septal ablation in hypertrophic cardiomyopathy utilizing a longitudinal 17-year study (mean 10.8). Observation follow-ups taken at a single medical centre. Wojtarowicz A; Kornacewicz-Jach Z Cardiol J; 2017; 24(2):125-130. PubMed ID: 27734458 [TBL] [Abstract][Full Text] [Related]
9. Predictors of long-term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction. Zhu C; Tang B; Cui H; Wang S; Xiao M; Chen Z; Meng Y; Zhao S; Song Y; Yu Q; Wang S J Card Surg; 2019 Jul; 34(7):533-540. PubMed ID: 31111576 [TBL] [Abstract][Full Text] [Related]
10. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. Liebregts M; Vriesendorp PA; Mahmoodi BK; Schinkel AF; Michels M; ten Berg JM JACC Heart Fail; 2015 Nov; 3(11):896-905. PubMed ID: 26454847 [TBL] [Abstract][Full Text] [Related]
11. Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathy. Liebregts M; Vriesendorp PA; Steggerda RC; Schinkel AF; Balt JC; Ten Cate FJ; Michels M; Ten Berg JM Catheter Cardiovasc Interv; 2016 Nov; 88(6):945-952. PubMed ID: 26946355 [TBL] [Abstract][Full Text] [Related]
12. Looking back on 15 years of ultrasound-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Vermaete I; Dujardin K; Stammen F Acta Cardiol; 2020 Oct; 75(6):483-491. PubMed ID: 31204591 [No Abstract] [Full Text] [Related]
13. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. ten Cate FJ; Soliman OI; Michels M; Theuns DA; de Jong PL; Geleijnse ML; Serruys PW Circ Heart Fail; 2010 May; 3(3):362-9. PubMed ID: 20332420 [TBL] [Abstract][Full Text] [Related]
14. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. Steggerda RC; Damman K; Balt JC; Liebregts M; ten Berg JM; van den Berg MP JACC Cardiovasc Interv; 2014 Nov; 7(11):1227-34. PubMed ID: 25326737 [TBL] [Abstract][Full Text] [Related]
15. Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Word of Balance. Sorajja P J Am Coll Cardiol; 2017 Jul; 70(4):489-494. PubMed ID: 28728695 [TBL] [Abstract][Full Text] [Related]
16. Alcohol septal ablation in obstructive hypertrophic cardiomyopathy: four years of experience at a reference center. Fiarresga A; Cacela D; Galrinho A; Ramos R; de Sousa L; Bernardes L; Patrício L; Cruz Ferreira R Rev Port Cardiol; 2014 Jan; 33(1):1-10. PubMed ID: 24405560 [TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Veselka J; Jensen MK; Liebregts M; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Tomasov P; Adlova R; Bundgaard H; Steggerda R; Ten Berg J; Faber L Eur Heart J; 2016 May; 37(19):1517-23. PubMed ID: 26746632 [TBL] [Abstract][Full Text] [Related]
18. Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy. Matsuda J; Kitamura M; Takayama M; Imori Y; Shibuya J; Kubota Y; Sangen H; Nakamura S; Takano H; Asai K; Shimizu W Heart Vessels; 2018 Mar; 33(3):246-254. PubMed ID: 28965135 [TBL] [Abstract][Full Text] [Related]